Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation

Eric Santoni-Rugiu*, Morten Grauslund, Linea C. Melchior, Junia C. Costa, Jens B. Sørensen, Edyta M. Urbanska

*Corresponding author for this work
12 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation'. Together they form a unique fingerprint.

Medicine & Life Sciences